Theranostic Focus Ariceum Therapeutics is a private radiopharmaceutical company at clinical stage, pursuing theranostic approaches for aggressive neuroendocrine and other hard-to-treat cancers, presenting opportunities to partner on diagnostic imaging and targeted radionuclide therapy.

Lead Candidates Lead assets include SSO110 labeled with 177Lu and 255Ac targeting SSTR2 for NETs and difficult cancers, plus ATT001 a radiolabeled PARP inhibitor; potential sales opportunities exist in co-development, licensing, or parallel supply for radiopharmaceutical components.

Strategic Partnerships Recent activity shows collaboration with Ipsen, ITM, NorthStar for Ac-225 supply, and Theragnostics acquisition, signaling openness to manufacturing partnerships, supply agreements, and joint development deals to secure radiopharmacy materials and platforms.

Global Footprint Headquartered in Berlin with operations across Europe, the U.S., Australia, and the UK; international presence creates opportunities for multi-region clinical collaborations, regulatory workstreams, and regional distribution or licensing arrangements.

Financial & Growth Funding of $52M with revenue in the $1–10M range and ongoing clinical programs indicate readiness for strategic investments, equity partnerships, or milestone-driven deals to accelerate clinical milestones and expand manufacturing and supply capabilities.